| identifies PRDM1 inactivation as a recurrent genetic defect in diffuse large B-cell lymphomas cells and establishes PRDM1 as a potential tumor suppressor gene. | lymphoma, |
| Blimp1 is a tumor suppressor gene, whose inactivation may contribute to lymphomagenesis by blocking post-germinal center differentiation of B cells toward plasma cells. | lymphoma, |
| PRDM1 may be a tumor suppressor in some primary central nervous system lymphoma and contribute to lymphomagenesis by impairing terminal differentiation | lymphoma, |
| BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. | lymphoma, |
| Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses. | neoplasm, |
| In vitro and in vivo experiments showed that that PRDM1 is a tumor suppressor gene in anaplastic large T-cell lymphoma models, likely acting as an antiapoptotic agent. | lymphoma, |
| Downregulation of the tumour suppressor PRDM1 in extranodal NK/T-cell lymphoma, nasal type, is mediated by miR-223. | lymphoma, |
| PRDM1, a Tumor-Suppressor Gene, is Induced by Genkwadaphnin in Human Colon Cancer SW620 Cells | colorectal, |
| Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies. | None |
| Blimp-1 is located in chromosome 6q21-22.1, a region frequently deleted in several tumors including lymphoid malignancies and has been supposed to be a candidate of tumor suppressor gene | None |
| both NF-kappaB signaling, as an oncogenic event, and BLIMP1, as a tumor suppressor, play causal roles in the pathogenesis of ABC-DLBCL. | None |
| PRDM1 is a tumor suppressor gene in natural killer cell malignancies. | None |
| results expand the spectrum of lymphoid malignancies in which PRDM1 may have a tumor suppressor role and identify an epigenetic event that likely contributes to the pathogenesis of BL. | None |